The U.S. Department of the Treasury and Internal Revenue Service have announced that more than 30 million taxpayers in 24 U.S. states will be eligible for Direct File in ...

Germany's construction sector activity contracted at the slowest pace in 16 months in September, survey results from S&P Global showed on Friday.The construction Purchasing Managers' ...

Creating opportunities for international cooperationHONG KONG, Oct 4, 2024 - (ACN Newswire) - The Hong Kong Film Development Council, Cultural and Creative Industries Development Agency and Hong Kong ...

On September 27th, the 16th Global Freight Forwarders Conference, organized by JCtrans, came to a successful conclusion. This grand event, which ...

Trilogy AI Corp. (CSE: TRAI) (OTCQB: TRAIF) (FSE: Y920) (formerly, Ambari Brands Inc.) (the "Company") is pleased to announce a non-brokered ...

CPF Group, Thailand's leading food conglomerate, in partnership with ImpactMind AI, today unveiled their pioneering "Bionic Organization" initiative.

The U.S. dollar extended gains against its major counterparts in the New York session on Thursday, as the nation's service sector activity climbed more than expected in September ...

The Azur Selection (ISIN: GRS528003007 Mnémonique: MLAZR), a Greek hotel company listed on the Euronext Access market in Paris, announces its half-year results for 2024. In the ...

DGB Group N.V. ("DGB" or "the Group") (Euronext: DGB: NL0009169515), a leading carbon project developer and ecosystem restoration company, announces the publication of its 2024 semi-annual consolidate ...

Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus - - Mary Beth ...

Q3-24 revenues of $12.6 million, down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23 Q3-24 adjusted EBITDA loss of $1.5 million compared ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ...